Michael R. Dougherty - 11 Jan 2023 Form 4 Insider Report for IDERA PHARMACEUTICALS, INC.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 11 Jan 2023
Net transaction value: +$14,750
SEC form: 4
Accepted by SEC: 12 Jan 2023, 19:00:10 UTC
Prior SEC filing: 05 Oct 2022
Next SEC filing: 20 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Michael R. Dougherty

Key filing fact

Michael R. Dougherty filed Form 4 for IDERA PHARMACEUTICALS, INC. on 12 Jan 2023.

Key facts

This page summarizes Michael R. Dougherty's Form 4 filing for IDERA PHARMACEUTICALS, INC..
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 12 Jan 2023, 19:00.

Change

Previous filing in this sequence was filed on 05 Oct 2022.
Current net transaction value: +$14,750.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IDRA transaction

Common Stock

Award

Transaction value: $14,750
Shares: +33,523
Change %: +9.8%
Price: $0.4400
Shares after: 375,155
Date: 11 Jan 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This stock was issued to the reporting person pursuant to his election, under the Issuer's director compensation program, to receive common stock in lieu of cash fees.